VIP and Palpitations: The most common adverse events were flushing, warm sensations, heart palpitations, and cold sensations (flushing: 20 [95%] during VIP vs 3 [14%] during placebo; P < .001; warm sensations: 20 [95%] during VIP vs 2 [10%] during placebo; P < .001; heart palpitations: 17 [81%] during VIP vs 1 [5%] during placebo; P < .001; cold sensations: 12 [57%] during VIP vs 0 during placebo; P = .02).